This inventor holds 1 USPTO granted patent. Top assignees: Diaclone, Efs Bourgogne Franche Comte, Université De Franche Comte. Active years: 2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:

Years Active: 2014
Title: The Innovative Mind of Christophe Borg
Introduction
Christophe Borg, an inventor from Pouillet les Vignes, France, is recognized for his groundbreaking work in cancer treatment. With one patent to his name, Borg has made significant strides in the field of medical biotechnology, focusing on the induction of p53 expression to combat cancerous cells.
Latest Patents
Christophe Borg's notable patent is titled "Induction of p53 expression by neutralization of neuropilin-2 for the treatment of cancers." This invention pertains to the use of anti-human neuropilin-2 antibodies or ligands derived from these antibodies. The proposed medicament aims to enhance p53 expression, effectively inducing apoptosis in tumor cells, which can substantially benefit anticancer treatment protocols.
Career Highlights
Throughout his career, Christophe Borg has contributed his expertise to respected institutions, including Diaclone and EFS Bourgogne Franche Comte. His experience in these companies has enabled him to collaborate with various professionals and make vital advancements in his field.
Collaborations
Borg has had the opportunity to work alongside notable colleagues, including John Wijdenes and Camille Grandclement. These collaborations have played an essential role in shaping his innovative approaches and furthering his research in cancer therapies.
Conclusion
Christophe Borg stands out as a dedicated inventor whose contributions have the potential to transform cancer treatment methodologies. His commitment to leveraging scientific innovation underscores the importance of continuous research and development in healthcare. As he continues to push the boundaries of medical technology, his work remains a valuable asset to the scientific community and beyond.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile